Vaxcyte, Inc.
PCVXNasdaqCIK 1649094HealthcareFiscal year ends Dec 31
Reports and events: 101 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-0920:42 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-419174 |
| 2026-10-0512:01 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-413168 |
| 2026-09-0320:18 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001649094-26-000045 |
| 2026-08-0520:13 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001649094-26-000043 |
| 2026-08-0520:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001649094-26-000041 |
| 2026-07-1520:05 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001649094-26-000030 |
| 2026-06-2320:09 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001649094-26-000026 |
| 2026-06-1620:12 ET | 8-K | 5.07 Shareholder vote results | 0001649094-26-000021 |
| 2026-05-0620:12 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001649094-26-000017 |
| 2026-05-0620:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001649094-26-000015 |
| 2026-04-2320:06 ET | DEF 14A | Proxy statementPeriod 2026-06-15 | 0001193125-26-173672 |
| 2026-02-2422:21 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-067546 |
| 2026-02-2421:37 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001649094-26-000007 |
| 2026-02-2421:14 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001649094-26-000005 |
| 2026-02-0221:01 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-033578 |
| 2025-12-1921:11 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001649094-25-000116 |
| 2025-11-0421:13 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001649094-25-000114 |
| 2025-11-0421:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001649094-25-000112 |
| 2025-09-3013:06 ET | 8-K | 1.01 Entry into a material agreement | 0001649094-25-000102 |
| 2025-08-0620:17 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001649094-25-000098 |
| 2025-08-0620:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001649094-25-000096 |
| 2025-06-1720:29 ET | 8-K | 5.07 Shareholder vote results | 0001649094-25-000084 |
| 2025-05-0720:23 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001649094-25-000074 |
| 2025-05-0720:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001649094-25-000073 |
| 2025-05-0112:16 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001649094-25-000057 |
| 2025-04-2820:01 ET | DEF 14A | Proxy statementPeriod 2025-06-12 | 0001193125-25-100425 |
| 2025-03-3112:36 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-067901 |
| 2025-02-2521:11 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001649094-25-000028 |
| 2025-02-2521:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001649094-25-000027 |
| 2024-11-2121:10 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events | 0001193125-24-263406 |
| 2024-11-0521:05 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001649094-24-000097 |
| 2024-11-0521:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001649094-24-000096 |
| 2024-09-0612:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-214711 |
| 2024-09-0312:04 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-211572 |
| 2024-08-0620:09 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001649094-24-000052 |
| 2024-08-0620:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001649094-24-000051 |
| 2024-07-0220:05 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-24-174317 |
| 2024-06-1020:19 ET | 8-K | 5.07 Shareholder vote results | 0001193125-24-158355 |
| 2024-05-0820:10 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0001628280-24-021677 |
| 2024-05-0820:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-24-021665 |
| 2024-04-1520:06 ET | DEF 14A | Proxy statementPeriod 2024-06-06 | 0001193125-24-096192 |
| 2024-02-2721:12 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-021145 |
| 2024-02-2721:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-021081 |
| 2024-01-3122:19 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-021084 |
| 2023-11-2813:32 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-23-283769 |
| 2023-11-2721:05 ET | 8-K | 1.01 Entry into a material agreement | 0001193125-23-283354 |
| 2023-11-0621:11 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0000950170-23-059395 |
| 2023-11-0621:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-059386 |
| 2023-10-1612:01 ET | 8-K | 1.01 Entry into a material agreement | 0001193125-23-256533 |
| 2023-10-0421:15 ET | 8-K | 1.01 Entry into a material agreement | 0001193125-23-250816 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.